Voyager Therapeutics, Inc. (VYGR) Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Voyager Therapeutics, Inc. NASDAQ:VYGR Healthcare · Biotechnology
Mkt Cap $105.98M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
Voyager Therapeutics announced two poster presentations at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference in Boston, November 16-19, 2026.
The posters will cover the first-in-human study design of VY1706, a BBB-penetrant tau-lowering gene therapy, and baseline data from a multiple ascending dose study of the anti-tau antibody VY7523, both in early Alzheimer's disease.
The release contains no new efficacy or safety data, so it is a visibility event ahead of the conference rather than a clinical milestone.
• 5d ago AI analysis › Press Release ⚠ 1
Voyager Announces CEO Succession Plan, Appoints Robin Swartz President
Voyager Therapeutics' board appointed Robin Swartz, currently Chief Business and Operating Officer, as President effective October 20, 2026, with a plan for her to succeed Alfred W. Sandrock, Jr. as CEO in Q1 2027.
The transition is tied to a key pipeline milestone: Dr. Sandrock is expected to remain CEO through initial acute safety data for VY1706, the company's tau silencing gene therapy in early Alzheimer's disease, anticipated in Q1 2027 pending enrollment.
Dr. Sandrock will stay on as a board member, and Swartz brings 26 years at Genzyme/Sanofi Genzyme plus five years at Voyager. The planned, orderly succession with an internal, board-unanimous pick limits leadership-disruption risk.
• 11d ago AI analysis › Press Release
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics announced its participation in five upcoming investor conferences, including events hosted by Wells Fargo, Morgan Stanley, and Baird. The fireside chats are scheduled between September 8 and September 15 in Boston and New York.
A webcast of the Wells Fargo session will be accessible via the company's website, with a replay available for 30 days.
Voyager is a biotechnology company developing genetic medicines for neurological diseases like Alzheimer's and Parkinson's, utilizing its TRACER platform. The company advances programs both independently and with partners such as Alexion, Novartis, and Neurocrine.
• 2mo ago AI analysis › Press Release ⚠ 1
Voyager Reports Second Quarter 2026 Financial and Operating Results
Voyager reported a narrower Q2 net loss of $24.5 million, compared to $33.4 million in the prior year, driven by program prioritization and reduced G&A expenses.
The company ended the quarter with $149 million in cash, sufficient to fund operations into 2028, while achieving IND clearance for VY1706 with dosing expected in Q4.
Pipeline progress includes anticipated tau PET data for VY7523 in Q4 and a planned H2 2026 clinical trial start for partner Neurocrine’s NBIB-‘223 program.
• 2mo ago AI analysis › Press Release
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
Voyager Therapeutics presented 6-month GLP toxicology data for VY1706 showing a favorable safety profile and up to 75% reduction in tau protein in key brain regions of non-human primates.
The company received FDA IND clearance for VY1706 in June, with dosing in a clinical trial for early Alzheimer's disease expected to begin in the second half of 2026.
VY1706 is a tau-targeted gene therapy delivered intravenously using Voyager's TRACER™ capsid, designed to cross the blood-brain barrier via the ALPL receptor.
• 3mo ago AI analysis › Press Release
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
Voyager Therapeutics announced that its tau-targeted gene therapy VY1706 will be featured in a late-breaking poster presentation at the Alzheimer's Association International Conference (AAIC) in July.
The presentation will cover IND-enabling GLP non-human primate study data, demonstrating a favorable tolerability profile up to the highest dose tested and tau protein reduction of up to 75% in relevant brain regions.
Following recent FDA IND clearance, Voyager plans to initiate a clinical trial in adults with early Alzheimer's disease, with dosing expected to begin in the second half of 2026.
• 4mo ago AI analysis › Press Release
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
Voyager Therapeutics announced that CEO Alfred Sandrock will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference.
The on-demand webcast of the chat will be available on Voyager’s investor relations website starting June 15, 2026, and will be archived for at least 30 days.
The release serves as a standard investor relations notification with no new clinical or financial disclosures.
• 4mo ago AI analysis › Press Release ● Major
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease
globenewswire.com • 5mo ago Press Release ● Major
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026
globenewswire.com • 5mo ago Press Release ● Major
Voyager Reports First Quarter 2026 Financial and Operating Results
globenewswire.com • 5mo ago Press Release
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease
Voyager Therapeutics announced upcoming presentations at ASGCT 2026, featuring preclinical data for its lead Alzheimer's candidate VY1706.
A late-breaking presentation will highlight 3-month GLP toxicology data for VY1706, demonstrating safety and pharmacology that supports an anticipated IND filing in Q2 2026 and first-in-human dosing in the second half of the year.
Additional presentations will showcase innovation across the TRACER platform, including muscular targeting, immune evasion, and manufacturing advancements.
• 6mo ago AI analysis › 
